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Summary. Type 3 von Willebrand’s disease (VWD) is a
rare bleeding diathesis with complete or near complete
deficiency of von Willebrand factor (VWF) and low
factor VIII (FVIII) levels. In contrast, only FVIII is
decreased in haemophilia A (HA). Both disorders are
complicated by arthropathy. The purpose of this study
was to further clarify the roles of FVIII and VWF:
Antigen (VWF:Ag) in joint range of motion (ROM) loss
over time. We compared joint ROM loss and other
bleeding manifestations in 100 Type 3 VWD subjects
(FVIII<5%) and 1814 moderate HA subjects (FVIII 1–
5%) within the U.S. Universal Data Collection (UDC)
database. High rates of bleeding were reported at
baseline. During follow-up, moderate HA patients
reported a joint (46% vs. 34%, P < 0.0001) or muscle
bleed (27% vs. 16%, P < 0.0001) in a higher
proportion of visits than VWD patients. Other bleeds,
including mucosal, were reported in a greater
proportion of visits among patients with Type 3 VWD
than among those with HA (49% vs. 32%,
P < 0.0001). Multivariate analysis revealed no
difference in joint ROM loss over time in the Type 3
VWD vs. moderate HA populations. A higher FVIII
level was protective in both VWD and HA (P < 0.001).
Our findings support the hypothesis of primacy of the
FVIII level in determining risk of joint haemorrhage,
and may help target therapy in Type 3 VWD and
moderate HA to prevent joint disability.
Keywords: arthropathy, factor VIII, joint range of
motion, moderate haemophilia A, von Willebrand factor,
von Willebrand’s disease
Introduction
Type 3 von Willebrand’s disease (VWD) is a rare
autosomal recessively inherited bleeding diathesis with
an estimated prevalence of 1–5 per million, character-
ized by complete or almost complete deficiency of von
Willebrand factor (VWF) [1]. As VWF is the carrier
for the Factor VIII (FVIII) molecule, FVIII:C levels are
also generally <10% in Type 3 disease [2,3].
As with other forms of VWD, most patients present
with mucocutaneous bleeding [4]. However, unlike Type
1 or 2 VWD, joint bleeding has been reported as a prom-
inent symptom (rates 37–45%) [4–7]. In 1926, Erik von
Willebrand first described a traumatic ankle bleed in
Hj€ordis, the original Aland Island proband with Type 3
VWD who bled to death from menorrhagia [8].
A survey of Type 3 VWD patients in U.S. Hemophilia
Treatment Centers (HTC) found a joint bleeding rate of
40.9% and evidence of morbidity including 28.2% tar-
get joints, and 5.6% invasive joint procedures [6]. Recur-
rent haemarthroses lead to arthropathy, characterized by
pain, joint degeneration and loss of range of motion
(ROM). Radiographic findings in chronic arthropathy
are similar to haemophilia [9]. ROM loss is higher in
Type 3 VWD compared with Type 1 or 2, with ankles
and hips the most predominantly affected joints [10,11].
In 1997, the Centers for Disease Control (CDC)
established the Universal Data Collection (UDC) study
which tracked joint complications in patients with
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bleeding disorders. In a previous analysis conducted by
our group using the UDC database, we found high rates
of joint bleeding (45%) in subjects with severe VWD,
consistent with previous cohorts [12]. Low FVIII
( 5%) and low VWF:Ag (<1%) both positively corre-
lated with higher rates of joint bleeding and were signif-
icantly associated with higher rates of joint ROM loss
in a longitudinal model. Further clarification of the
individual contributions of the FVIII and VWF:Ag to
joint ROM loss, potentially modifiable variables which
may influence the optimal choice and dose of replace-
ment factor concentrate, could not be performed in this
population due to concerns of collinearity.
Type 3 VWD patients have similar FVIII values to
moderate haemophilia A (HA) of 1–5% [5]. Unlike
VWD, HA patients have normal VWF levels. Joint bleed-
ing, often traumatic, has long been recognized as a signif-
icant symptom in moderate HA. A cross-
sectional study in the UDC including 1048 subjects age
<20 with moderate haemophilia A and B found that
37.8% had asymmetrically mobile joints, and joint
ROM limitation increased with age, body mass index
(BMI) and non-white race [13]. FVIII level was not inde-
pendently considered a variable in that study, but higher
FVIII levels have been associated with decreased long-
term joint damage as assessed by radiologic Pettersson
scoring in a Dutch moderate haemophilia cohort [14].
To further clarify the roles of FVIII and VWF:Ag,
we established two cohorts of patients with similar
FVIII levels using the UDC database. The purpose of
this retrospective cohort study was to compare joint
ROM loss and other bleeding symptoms in the moder-
ate haemophilia A and Type 3 VWD populations, and
to evaluate the contribution of the FVIII level to joint
ROM over time in these subjects.
Materials and methods
Patients and methods
Between 1997 and 2011, the UDC was administered
through the ~140 federally funded HTCs within the U.S.
and its territories; participation was approved by the
Institutional Review Board of each HTC and the CDC.
Study subjects completed a standardized registration
form upon enrolment (which occurred at any age),
including demographics, diagnosis, baseline factor activ-
ity, retrospective recollection of first bleeding symptoms
and joint ROM. UDC participation was offered annu-
ally; the number of new bleeds, treatment, BMI and joint
ROM were among items documented. All participants
gave written informed consent before enrolment.
Patients. The method of identifying VWD patients
has previously been described in detail [12]. In brief,
subjects were initially identified by diagnosis of ‘Type
3 VWD’ on the UDC registration form. HTCs were
then contacted directly to obtain baseline laboratory
values to validate this diagnosis. A ‘severe VWD’
cohort of subjects with VWF:Ag value <10% was
included in the prior study [12]. Among VWD
patients with a validated diagnosis, only those with a
FVIII level 5% were selected for inclusion in this
analysis. This cohort was designated ‘Type 3 VWD’.
As a comparison group, all subjects with moderate
HA, identified by diagnosis and baseline FVIII activity
level between 1% and 5%, were selected.
Inclusion/exclusion criteria. Study subjects were
required to have a validated diagnosis of severe VWD
or moderate HA, as defined above. Subjects with
insufficient information, history of inhibitor, another
bleeding disorder, or BMI > 35 (because of inaccuracy
in joint ROM measurement) were excluded.
Data collection. Data were included from the Regis-
tration and Annual Visit forms of subjects from 1997
to 2007. FVIII activity level was a continuous vari-
able. Orthopaedic appliances include casts, splints,
orthotics and braces. Invasive joint procedures include
arthrodesis, joint replacement, synovectomy, or other.
Collection of joint ROM has been described previ-
ously [12,13]. Briefly, 10 joints (bilateral shoulders,
elbows, hips, knees and ankles) are passively moved
to their fullest extent and ROM is recorded. Left- and
right-sided joints were averaged and then each joint
ROM measure was divided by its reference value from
the gender-specific normal population aged 12–20
[15]. The overall joint ROM proportion was the
average of the 10 joint-specific proportions, to gain a
summary measure for each individual.
Statistical analysis. Univariate analyses were carried
out with the student t-test and chi-squared test for con-
tinuous and categorical variables respectively. Factors
related to joint ROM loss over time were explored with
the mixed model for continuous outcome variable with
repeated measurements. A backward stepwise elimina-
tion strategy was used to generate a predictive model.
The marginal model was employed to investigate fac-
tors associated with episodic bleeding occurrence dur-
ing follow-up. Sensitivity analyses included evaluation
of Type 3 VWD subjects with FVIII 1–5% (vs. 5%)
and removal of the invasive procedure variable in uni-
variate and multivariate analyses. All analyses were per-
formed using Statistical Analysis Software (SAS)
version 9.1 (SAS Institute, Cary, NC).
Results
Study population
One hundred subjects with Type 3 VWD and 1814
subjects with moderate HA that met our prespecified
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criteria were identified within the UDC database. Soci-
odemographic information at enrolment is listed in
Table 1. As expected, the Type 3 VWD group included
many more women (0.9% HA vs. 49.0% VWD). The
HA population was more racially diverse. Mean FVIII
levels were similar (HA 2.9%  1.3 vs. VWD
2.6%  1.4, P = ns), as was the age of registration.
Bleeding characteristics at baseline
High percentages of patients with both moderate HA
and Type 3 VWD reported a history of any bleeding
at the time of registration (97.7% vs. 99.0%).
Figure 1 shows bleeding symptoms at registration
(which can occur at any age). Both groups demon-
strate a strong bleeding phenotype, with similar rates
of intracranial haemorrhage. Moderate HA subjects
reported higher rates of family history of bleeding dis-
order, home factor infusion and prophylaxis usage
(20.9% vs. 12.0%, P = 0.03). Type 3 VWD subjects
were more likely to have ever required blood products
or factor overall, and retrospectively report mucosal
bleeding or bleeding after an intramuscular (IM) injec-
tion as the first site of bleeding (Fig. 2). In compari-
son, moderate HA subjects experienced higher rates of
initial intracranial and extracranial bleeding. There
was a non-significant trend towards a higher number
of initial joint bleeds in the HA population (11.1% vs.
6%, P = 0.11). Employment status was similar at reg-
istration (HA vs. VWD, 25.2% vs. 25.0% reported a
full or part-time job, P = 0.97), as was use of a cane
(19.7% vs. 17%, P = 0.45) or wheelchair (4.9% vs.
5%, P = 0.86). Few patients reported a history of
joint infection (0.66% HA vs. 0% VWD) at registra-
tion.
Bleeding characteristics during follow-up
Data from annual forms were available for a mean of
3.4 years (range 0–9.44). The mean follow-up time
was 3.2 years for HA and 3.9 years for VWD
(P = 0.001). During this period, the proportion of vis-
its in which the patient reported at least one bleed
was higher in the moderate HA vs. Type 3 VWD pop-
ulation for joint (46% vs. 34%, P < 0.0001) and mus-
cle bleeding (27% vs. 16%, P < 0.0001). Other
bleeds, including mucosal, were higher in the Type 3
VWD vs. HA group (49% vs. 32%, P < 0.0001).
More VWD than HA patients reported at least one
invasive joint procedure at a follow-up visit (6% vs.
4%, P = 0.05), with slightly more synovectomy,
arthrodesis and other. Distribution of joint replace-
ment and orthopaedic appliance usage was similar
(Fig. 3).
Risk factors for joint range of motion loss over
time
Longitudinal multivariate analysis showed no differ-
ence in joint ROM loss over time between individuals
with VWD and moderate HA when controlled for
Table 1. Sociodemographic information at enrolment.
Moderate
haemophilia
A (n = 1814)
VWD Type 3
(n = 100) P value
Race
White 1200 (66.2) 84 (84.0) 0.0002
African-American 216 (11.9) 4 (4.0)
Hispanic 268 (14.8) 2 (2.0)
Other 130 (7.2) 10 (10.0)
Gender
Female 17 (0.9) 49 (49.0) <0.0001
Male 1797 (99.1) 51 (51.0)
Factor VIII activity
level* (mean, SD)
2.9 (1.3) 2.6 (1.4) 0.12
Age (years)
Registration (mean, SD) 19.1 (15.9) 21.9 (17.0) 0.09
Range (2–69) (3–69)
First bleed (mean, SD) 2.5 (4.7) 2.0 (5.6) 0.45
Data presented as Mean (%) unless otherwise specified.
*4 patients with VWD did not have explicit FVIII levels and were
excluded from this analysis.
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Fig. 1. Bleeding symptoms at registration.
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age, race, gender, FVIII level, BMI, use of prophylaxis
and history of invasive joint procedures or orthopae-
dic appliances. Higher FVIII level was associated
with preserved joint ROM (P < 0.001). Lower FVIII
level correlated with a higher rate of joint [OR (95%
CI), 0.77 (0.73–0.82), P < 0.001] and muscle [0.84
(0.79–0.90), P < 0.001], but not mucosal bleeding
[0.96, (0.91–1.01), P = 0.10].
There was no significant difference in joint ROM
loss between the groups when upper and lower
extremities were evaluated separately or when ankles,
a problematic joint in VWD, were analysed alone.
Subset analysis in subjects age <20, comprising 68%
and 54% of all HA and VWD subject visits, respec-
tively, again found no difference in joint ROM loss
over time in the Type 3 VWD vs. moderate HA popu-
lation (results not shown). As a sensitivity analysis,
Type 3 VWD subjects with FVIII 1–5% (334 visits)
vs.  5% (390 visits), were also evaluated, which did
not change the direction of estimated parameters or
the significance of any included variables. Similarly,
analysis with removal of the invasive procedure vari-
able did not change the model.
Discussion and conclusion
We utilized a large U.S. database of patients with
bleeding disorders to compare joint dysfunction in
patients with Type 3 VWD and moderate HA. FVIII
levels, pattern of bleeding symptoms at registration
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Fig. 3. Bleeding events during follow-up: propor-
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and age at first bleed and at registration were very
similar in the groups, supporting their comparability.
In our analysis, we found no difference in joint
function limitation, as defined by ROM loss, in the
Type 3 VWD and moderate HA populations over
time. The diagnosis of VWD or HA remained non-
significant in both the full and reduced longitudinal
multivariate models, as well as in subset analyses.
There was a trend towards an increased number of
haemarthroses as the initial bleed site and a significant
increase in visits with a reported joint bleed during
the follow-up period in the HA patients.
Joint bleeding is characteristic of haemophilia,
whereas patients with VWD more typically experience
platelet-mediated mucosal bleeding. Joints may be par-
ticularly prone to bleed in FVIII deficiency due to the
critical role of the coagulation system in the synovi-
um: cryptic tissue factor expression allows only lim-
ited factor VIIa binding leading to inadequate
thrombin burst in the absence of FVIII, compounded
by high amounts of tissue factor pathway inhibitor
expression [16,17]. On the other hand, once bleeding
has occurred, the cycle of synovial inflammation,
hypertrophy and cartilage and bone destruction
begins, leading to recurrent haemarthroses and joint
ROM limitations over time [18].
Factor VIII was included in the analysis as a contin-
uous variable, and increasing levels were associated
with joint function preservation in both groups. Lower
FVIII also correlated with increased joint and muscle,
but not mucosal, bleeding in both groups. In a previ-
ous study in severe VWD (VWF:Ag < 10%), we found
that both low FVIII ( 5%) and low VWF:Ag (<1%)
levels were associated with higher rates of joint bleed-
ing and ROM loss over time [12]. Lower FVIII levels
have been previously shown to correlate with
increased joint damage in moderate HA patients as
well [14]. Given that VWD and HA patients have very
similar FVIII levels but different VWF levels, the FVIII
level appears to be the more important contributor to
joint function over time. It is thus possible that the
VWF protein may function only in its secondary role
in the synovium, as a carrier for FVIII.
Lak et al. compared 385 Iranian subjects with Type
3 VWD to 100 subjects with severe HA [5]. They
found that haemarthrosis was common in VWD, but
less than severe HA (37% vs. 86%, P < 0.0001). The
authors speculated that the higher FVIII levels in the
VWD cohort (1–9%, median 4%) may account for
some of these differences. In contrast, we compared
Type 3 VWD subjects with FVIII levels 5% to mod-
erate HA (FVIII levels 1–5%), to control for this vari-
able. Our finding that rates of ROM loss were similar
supports the hypothesis of the primacy of the FVIII
level.
Although joint ROM loss was similar, some clear
differences between the VWD Type 3 and moderate
HA groups were identified in our analysis. Patients
with moderate HA were more likely to use home infu-
sion as well as prophylaxis, although a higher percent-
age of Type 3 VWD patients reported any use of blood
products and factor overall. This may reflect increased
physician experience and comfort with prophylaxis in
HA, particularly with availability of recombinant FVIII
products, as well as difficulty in obtaining insurance
coverage for prophylaxis in VWD.
As expected, mucosal bleeding was much more com-
mon as a first site of bleeding in VWD. Bleeding after
IM injection was also higher; perhaps less reported fam-
ily history of bleeding disorder may have led to inade-
quate precautions with this procedure. Initial
intracranial and extracranial bleeds were higher in
moderate HA. During follow-up, Type 3 VWD subjects
continued to report high rates of mucosal bleeding. Sig-
nificantly more moderate HA patients had a visit in
which they reported at least one joint or muscle bleed.
Interestingly, slightly more invasive procedures were
reported by VWD patients, but placement of orthopae-
dic appliances was similar. In light of the equivalent
joint ROM limitation, these findings suggest that VWD
patients may not be adequately trained to recognize
joint bleeds, and thus may underreport them.
The two groups differed substantially in terms of
gender, with significantly more women in the Type 3
VWD group. The 17 moderate HA women were pre-
sumably symptomatic carriers with high degrees of
lyonization. Longitudinal joint ROM regression analy-
sis was consistent with our previous finding that male
gender is significantly negatively associated with joint
ROM in severe VWD [12], and a study of joint ROM
in normal subjects, in which females have higher joint
flexibility than males at all age groups in nearly all
joints [15].
Strengths of our analysis include the relatively large
number of subjects with HA and Type 3 VWD, a rare
bleeding disorder and the ability to follow joint ROM
in individuals over time. As a sensitivity analysis, Type
3 VWD subjects with FVIII 1–5% (vs.  5%) were
evaluated, which did not change the outcomes. The
U.S. population is heterogeneous and likely includes
patients with a variety of genetic mutations, which
helps improve the generalizability of our findings [19].
An important limitation is that the UDC had tradi-
tionally been oriented towards haemophilia although
it includes all inherited bleeding disorders. As such,
although we were able to distinguish mucosal bleeding
symptoms at registration, mucosal bleeding during fol-
low-up was in the ‘other’ category (which we presume
was predominantly mucosal). The small absolute sam-
ple size of female subjects, and of patients with Type
3 VWD, limited more detailed statistical analysis.
Amount of factor used, another potentially confound-
ing variable, could not be analysed as quantitative
data were not included in the UDC. Slightly more
© 2013 John Wiley & Sons Ltd Haemophilia (2013), 19, 595--601
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patients with VWD had an invasive procedure. This
variable was controlled for in multivariate analysis,
and sensitivity analysis did not find a difference in
ROM difference between VWD and HA when it was
excluded. We had insufficient power to further analyse
the influence of invasive procedure types on ROM due
to large variation in procedure types and joints.
Finally, our definition of ‘Type 3 VWD’ was con-
strained by baseline local labs. Local laboratories used
different methods and reported different lower levels
of sensitivity for VWF:Ag (i.e. <5 vs. <1 IU dL1). Of
those patients with a discrete or undetectable VWF:Ag
level (n = 63/100), the mean (SD) VWF:Ag level was
1.4 IU dL1 (2.5), consistent with current guidelines
[2]. As VWF:Ag is not routinely measured in HA
patients, it could not be included as an independent
variable in the study.
Our finding of significant joint function limitation
in both the Type 3 VWD and moderate HA popula-
tions suggests a potential role for increased prophy-
laxis. Whereas prophylaxis in severe haemophilia is
extensively used, data regarding prophylaxis in severe
VWD patients remain scant. A 2005 census of 305
Type 3 VWD patients in Europe and North America
found that of the 99 patients who started prophylaxis
in the prior 12 months, 41.4% were for joint-related
issues [20]. In our study, relatively few patients with
Type 3 VWD used prophylaxis during the study
period (12.0%).
Limited data thus far indicate that prophylaxis may
benefit patients with VWD including secondary prophy-
laxis in several small European cohorts [20–25]. Fur-
ther information will be forthcoming from the von
Willebrand’s disease Prophylaxis Network (vWD PN),
which includes both a registry tracking use of
prophylaxis, and the prospective VWD International
Prophylaxis Study using a VWF-containing concentrate
1–3 times per week [26]. Results from the study thus
far demonstrate significantly lower annualized rates of
joint bleeding with prophylaxis in 59 individuals,
including 34 (57.6%) with Type 3 VWD [27].
In summary, we found that subjects with Type 3
VWD and moderate HA develop similar rates of joint
function limitation over time. An important poten-
tially modifiable variable identified was the FVIII level,
suggesting that a low VWF:Ag may not contribute
any additional risk to joint function limitation in the
Type 3 VWD population. Studies are needed to fur-
ther define risk factors in both the Type 3 VWD and
moderate HA populations, and identify a subgroup
that would benefit from risk modification and/or pro-
phylaxis to avoid the development of disabling
arthropathy.
Acknowledgements
This work was supported by NHLBI K12HL087064 (to SLS) and
T32HL07971-08 (to AC), HTRS Mentored Research Award (to ADM),
and by Cooperative Agreement #U27/CCU318053 from the CDC (to
BAK).
Author contributions
BAK conceived the original study question. SLS, AC, ADM and BAK
designed the study, and validated the study population. CW performed
primary data analysis, with assistance from JMS, and input from all
authors. All authors had access to data. SLS wrote the manuscript, with
substantial input and modification from all authors.
Disclosures
Some of the authors have received funding from manufacturers of factor
products used to treat HA and VWD. CSL Behring (consultancy: BK,
research studies: BK, SLS), Baxter Healthcare (consultancy and research
studies: BK, AC), Bayer Corporation (research studies: AC), Biogen-Idec
(consultancy and research studies: BK).
References
1 Sadler JE, Budde U, Eikenboom JC et al.
Update on the pathophysiology and classifi-
cation of von Willebrand disease: a report
of the subcommittee on von Willebrand Fac-
tor. J Thromb Haemost 2006; 4: 2103–14.
2 Nichols WL, Hultin MB, James AH et al.
von Willebrand disease (VWD): evidence-
based diagnosis and management guide-
lines, the National Heart, Lung, and Blood
Institute (NHLBI) expert panel report
(USA). Haemophilia 2008; 14: 171–232.
3 Weiss HJ, Sussman II, Hoyer LW. Stabil-
ization of factor VIII in plasma by the von
Willebrand factor. Studies on posttransfu-
sion and dissociated factor VIII and in
patients with von Willebrand’s disease. J
Clin Invest 1977; 60: 390–404.
4 Federici AB. Diagnosis of inherited von
Willebrand disease: a clinical perspective.
Semin Thromb Hemost 2006; 32: 555–65.
5 Lak M, Peyvandi F, Mannucci PM. Clinical
manifestations and complications of child-
birth and replacement therapy in 385 Ira-
nian patients with type 3 von Willebrand
disease. Br J Haematol 2000; 111: 1236–9.
6 Sumner M, Williams J. Type 3 von Wille-
brand disease: assessment of complications
and approaches to treatment – results of a
patient and Hemophilia Treatment Center
Survey in the United States. Haemophilia
2004; 10: 360–6.
7 Ahlberg A, Silwer J. Arthropathy in von
Willebrand’s disease. Acta Orthop Scand
1970; 41: 539–44.
8 Von Willebrand EA. Hereditary pseudohae-
mophilia. Haemophilia 1999; 5: 223–31
discussion 2.
9 Sankarankutty M, Evans DI. Chronic
arthropathy in von Willebrand’s disease.
Clin Lab Haematol 1983; 5: 149–56.
10 Abshire TC. Prophylaxis and von Wille-
brand’s disease (vWD). Thromb Res 2006;
118(Suppl 1): S3–7.
11 Soucie JM, Forsyth A, Watson C, Wang C,
U.D.C. Investigators. Joint Range of
Motion (ROM) measurements in patients
with von Willebrand disease compared
with normal subjects. J Thromb Heamost
2007; 5(Suppl. 2): P-W-188.
12 Metjian AD, Wang C, Sood SL et al. Bleed-
ing symptoms and laboratory correlation in
patients with severe von Willebrand dis-
ease. Haemophilia 2009; 15: 918–25.
13 Soucie JM, Cianfrini C, Janco RL et al. Joint
range-of-motion limitations among young
males with hemophilia: prevalence and risk
factors. Blood 2004; 103: 2467–73.
14 Fischer K, van der Bom JG, Mauser-Bun-
schoten EP et al. Endogenous clotting fac-
tor activity and long-term outcome in
patients with moderate haemophilia.
Thromb Haemost 2000; 84: 977–80.
15 Soucie JM, Wang C, Forsyth A et al. Range
of motion measurements: reference values
and a database for comparison studies.
Haemophilia 2011; 17: 500–7.
Haemophilia (2013), 19, 595--601 © 2013 John Wiley & Sons Ltd
600 S. L. SOOD et al.
16 Brinkmann T, Kahnert H, Prohaska W,
Nordfang O, Kleesiek K. Synthesis of tissue
factor pathway inhibitor in human synovial
cells and chondrocytes makes joints the predi-
lected site of bleeding in haemophiliacs. Eur J
Clin Chem Clin Biochem 1994; 32: 313–7.
17 Berckmans RJ, Nieuwland R, Tak PP et al.
Cell-derived microparticles in synovial fluid
from inflamed arthritic joints support coag-
ulation exclusively via a factor VII-depen-
dent mechanism. Arthritis Rheum 2002;
46: 2857–66.
18 Valentino LA, Hakobyan N, Enockson C.
Blood-induced joint disease: the confluence
of dysregulated oncogenes, inflammatory
signals, and angiogenic cues. Semin Hema-
tol 2008; 45: S50–7.
19 Lillicrap D. Genotype/phenotype associa-
tion in von Willebrand disease: is the glass
half full or empty?. J Thromb Haemost
2009; 7(Suppl 1): 65–70.
20 Berntorp E. Prophylaxis and treatment of
bleeding complications in von Willebrand
disease type 3. Semin Thromb Hemost
2006; 32: 621–5.
21 Berntorp E, Petrini P. Long-term prophylaxis
in von Willebrand disease. Blood Coagul
Fibrinolysis 2005; 16(Suppl 1): S23–6.
22 Berntorp E. Prophylaxis in von Willebrand dis-
ease.Haemophilia 2008; 14(Suppl 5): 47–53.
23 Federici AB. Prophylaxis of bleeding episodes
in patients with von Willebrand’s disease.
Blood Transfus 2008; 6(Suppl 2): s26–32.
24 Federici AB, Gianniello F, Canciani MT,
Mannucci PM Secondary long-term prophy-
laxis in severe patients with von Willebrand’s
disease: an Italian cohort study. ASH Annual
Meeting Abstracts 2005; 106: 1782.
25 Halimeh S, Krumpel A, Rott H et al.
Long-term secondary prophylaxis in chil-
dren, adolescents and young adults with
von Willebrand disease. Results of a
cohort study. Thromb Haemost 2011;
105: 597–604.
26 Berntorp E, Abshire T. The von Willebrand
disease prophylaxis network (vWD PN):
exploring a treatment concept. Thromb Res
2006; 118(Suppl 1): S19–22.
27 Abshire TC, Federici AB, Alvarez MT
et al. Prophylaxis in severe forms of von
Willebrand’s disease: results from the
von Willebrand Disease Prophylaxis Net-
work (VWD PN). Haemophilia 2013; 19:
76–81.
Supporting Information
Additional Supporting Information may be
found in the online version of this article:
Appendix S1. List of contributing investi-
gators.
© 2013 John Wiley & Sons Ltd Haemophilia (2013), 19, 595--601
JOINT LIMITATION IN TYPE 3 VWD VS. HAEMOPHILIA A 601
